European shares start August on sour note as global factory activity falters

By Sruthi Shankar, Amruta Khandekar and Shristi Achar A (Reuters) -European stocks fell on Tuesday, with the German DAX pulling back from record highs as shrinking factory activity in the euro zone, China and the United States underscored growing risks to the global economy from rising interest rates. The pan-European STOXX 600 index closed down…

Read More

Norwegian Cruise sails south as higher costs hit Q3 profit target

By Granth Vanaik (Reuters) -Norwegian Cruise Line on Tuesday forecast downbeat third-quarter profit after a strong second quarter, as elevated costs offset gains from robust demand and higher ticket prices, sending the company’s shares tumbling down as much as 16.7%. While higher costs have hounded most cruise operators, they have also benefited from pent-up demand…

Read More

Top US utility group opposes emissions plan for existing gas plants-source

By Nichola Groom and Valerie Volcovici WASHINGTON (Reuters) -The top U.S. utility lobby group intends to push back against the Biden administration’s proposals requiring upgrades to existing natural gas-fired power plants to curb climate-warming emissions, two sources familiar with the matter said. Resistance from the Edison Electric Institute (EEI), which represents investor-owned utilities that serve…

Read More

Enterprise reports lower Q2 earnings as margins tighten

By Stephanie Kelly NEW YORK (Reuters) -U.S. energy infrastructure group Enterprise Products Partners LP reported lower earnings for the second quarter due to a major year-on-year drop in the price of natural gas liquids, which affected margins, the company said on Tuesday. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for the second quarter…

Read More

Merck raises 2023 sales forecast as top drugs beat Street estimates

By Michael Erman and Leroy Leo (Reuters) -Merck & Co raised its full-year revenue forecast on Tuesday as second-quarter sales of its top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil, sailed past Wall Street estimates. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts’ average estimate of…

Read More